• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Eargo Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    2/16/24 8:42:56 AM ET
    $EAR
    Medical Specialities
    Health Care
    Get the next $EAR alert in real time by email
    false12-31000171939500017193952024-02-162024-02-16

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549



    FORM 8-K



    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): February 16, 2024



    EARGO, INC.
    (Exact name of Registrant as Specified in Its Charter)



    Delaware
    (State or Other Jurisdiction
    of Incorporation)
    001-39616
    (Commission File Number)
    27-3879804
    (IRS Employer
    Identification No.)
         
    2665 North First Street, Suite 300
    San Jose, California
    (Address of Principal Executive Offices)
     
    95134
    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (650) 351-7700

    (Former Name or Former Address, if Changed Since Last Report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.0001 par value per share
     
    EAR
     
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Introduction

    As previously disclosed, Eargo, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger, dated as of October 29, 2023 (the “Merger Agreement”), with PSC Echo Parent LLC, a Delaware limited liability company (“Parent”), and PSC Echo Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). On February 16, 2024 (the “Closing Date”), upon the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the applicable provisions of the Delaware General Corporation Law (the “DGCL”), Merger Sub merged with and into the Company, with the Company surviving such merger as the surviving corporation (the “Merger”).

     
    Item 2.01
    Completion of Acquisition or Disposition of Assets.

    The information set forth in the Introduction of this Current Report on Form 8-K is incorporated by reference in this Item 2.01.

    Closing of the Merger

    On the Closing Date, Parent completed the acquisition of the Company. Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of common stock, $0.0001 par value per share, of the Company (the “Company Common Stock”) issued and outstanding immediately prior to the Effective Time, other than certain excluded shares pursuant to the terms of the Merger Agreement, was cancelled and extinguished and automatically converted into and shall thereafter represent the right to receive an amount in cash equal to $2.55 per share of Company Common Stock (the “Merger Consideration”), payable to the holder thereof, without interest and subject to applicable tax withholding, subject to and in accordance with the terms and conditions of the Merger Agreement.

    In addition, at the Effective Time, each option to purchase shares of Company Common Stock granted by the Company that was outstanding and unexercised immediately prior thereto, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest and subject to applicable tax withholding, equal to the product obtained by multiplying (A) the aggregate number of shares of Company Common Stock subject to such option immediately prior to the Effective Time by (B) the excess, if any, of the Merger Consideration over the exercise price per share of such option. Any option that had a per share exercise price that was greater than or equal to the Merger Consideration was cancelled for no consideration as of the Effective Time. At the Effective Time, each Company RSU Award (as defined in the Merger Agreement) granted by the Company that was outstanding immediately prior thereto was cancelled and converted into the right to receive an amount in cash, without interest and subject to applicable tax withholding (the “RSU Cash Replacement Award”), equal to the product obtained by multiplying (A) the aggregate number of shares of Company Common Stock subject to such option immediately prior to the Effective Time by (B) the Merger Consideration, less any applicable tax withholding. Subject to certain exceptions, such RSU Cash Replacement Awards have the same terms and conditions (including with respect to vesting) as applied to the Company RSU Award for which they were exchanged.


    The foregoing description of the Merger and the Merger Agreement, and the transactions contemplated thereby, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement which is attached as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 30, 2023 and incorporated herein by reference into this Item 2.01.

     
    Item 3.01
    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    The information set forth in the Introduction of this Current Report on Form 8-K is incorporated by reference in this Item 3.01.

    In connection with the closing of the Merger, the Company notified NASDAQ Stock Market (“Nasdaq”) that the Merger had been consummated and, as a result, trading of the Company’s securities on Nasdaq has been halted prior to the opening of Nasdaq on the Closing Date. The Company requested Nasdaq to file with the SEC a notification of removal from listing and registration on Form 25 with the SEC to effect the delisting of the Company’s securities from Nasdaq and the deregistration of the Company’s securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company intends to file with the SEC a Form 15 suspending the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

     
    Item 3.03
    Material Modification to Rights of Security Holders.

    The information set forth in the Introduction and under Item 2.01  and Item 5.03 of this Current Report on Form 8-K is incorporated by reference in this Item 3.03.

     
    Item 5.03
    Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year.

    At the Effective Time, (i) the Company’s certificate of incorporation was amended and restated in its entirety and (ii) the Company’s bylaws were amended and restated in their entirety, each in accordance with the terms of the Merger Agreement and the DGCL.

    Copies of the Amended and Restated Certificate of Incorporation of the Company and the Amended and Restated Bylaws of the Company are filed as Exhibits 3.1 and 3.2 hereto, respectively, and are incorporated herein by reference.

     
    Item 8.01
    Other Events.

    On February 16, 2024, the Company issued a press release (the “Press Release”) announcing the closing of the Merger.

    A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

    Item 9.01
    Financial Statements and Exhibits.

    Exhibit No.
     
    Description
    2.1
     
    Agreement and Plan of Merger, dated as of October 29, 2023, by and among PSC Echo Parent LLC, PSC Echo Merger Sub Inc. and Eargo, Inc. (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on October 30, 2023).
    3.1
     
    Amended and Restated Certificate of Incorporation of Eargo, Inc.
    3.2
     
    Amended and Restated Bylaws of Eargo, Inc.
    99.1
     
    Press Release, Dated February 16, 2024.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    EARGO, INC.
           
           
    Date:
    February 16, 2024
    By:
    /s/ William Brownie
         
    William Brownie
    Interim Chief Executive Officer and
    Chief Operating Officer

    Get the next $EAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EAR

    DatePrice TargetRatingAnalyst
    9/23/2021Outperform → Mkt Perform
    William Blair
    9/23/2021$11.00Overweight → Underweight
    JP Morgan
    9/23/2021$10.00Overweight → Equal-Weight
    Wells Fargo
    More analyst ratings

    $EAR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Eargo Inc.

      15-12G - Eargo, Inc. (0001719395) (Filer)

      2/26/24 1:39:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:18 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:16 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

      SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1

      1/31/24 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

      SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th

      11/1/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

      SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues

      10/26/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Brownie William returned 296 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:03:54 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Narula Onkarr

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:01:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Wu David James returned 25,463 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 5:59:27 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $EAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Eargo downgraded by William Blair

      William Blair downgraded Eargo from Outperform to Mkt Perform

      9/23/21 7:17:15 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by JP Morgan with a new price target

      JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00

      9/23/21 5:05:21 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00

      9/23/21 5:03:59 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Eargo Appoints Katie Bayne to Board of Directors

      SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos

      6/10/21 4:30:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      2/16/24 11:30:56 AM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      10/30/23 5:21:26 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Eargo Inc. (Amendment)

      SC 13G/A - Eargo, Inc. (0001719395) (Subject)

      1/6/23 11:49:44 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Financials

    Live finance-specific insights

    See more
    • Eargo Reports Second Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will

      8/10/23 4:05:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Reports First Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported

      5/11/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo to Report First Quarter 2023 Financial Results on May 11, 2023

      SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s

      5/4/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care